Defunct Company
Total Trials
9
As Lead Sponsor
8
As Collaborator
1
Total Enrollment
872
NCT04798677
Efficacy and Tolerability of ABBC1 in Volunteers Receiving the Influenza or Covid-19 Vaccine
Phase: N/A
Role: Lead Sponsor
Start: Oct 29, 2020
Completion: Sep 24, 2021
NCT05389761
Fibromyalgia Treatment With Enzyme DAO
Role: Collaborator
Start: Feb 22, 2022
Completion: Nov 18, 2022
NCT06738420
Medical Nutrition Formulations Enriched With Postbiotics for the Management of Gastrointestinal Disorders
Start: Jan 27, 2023
Completion: Apr 4, 2024
NCT06710366
Prevalence of DAO (diamino Oxidase) Deficiency in Newborns
Start: Feb 28, 2023
Completion: Jun 26, 2024
NCT06738433
Efficacy and Tolerability of ABB I5 Prebiotic and ABB C22 Postbiotics for the Management of Constipation and Gastrointestinal Well-being: a Pilot Trial
Phase: Early Phase 1
Start: Apr 25, 2023
NCT06488027
DAO DEFICIENCY SCREENING AMONG PATIENTS WITH INSOMNIA SYMPTOMS
Start: May 5, 2023
Completion: Nov 27, 2023
NCT07006558
Kinetic Study Of Supplementation With The Enzyme Diamine Oxidase In Patients With Histamine Intolerance
Start: Jun 23, 2023
Completion: Aug 5, 2024
NCT07027943
Evaluation Of The Diamine Oxidase Supplementation Effect In Patients With Insomnia Symptoms
Start: Mar 13, 2024
Completion: Dec 18, 2024
NCT06715163
Evaluation of the Safety and Tolerability of Three Doses of Diamine Oxidase (DAO) in Healthy Volunteers
Start: Jul 8, 2024
Completion: Jul 29, 2024